AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

François Lux*, Vu Long Tran, Eloïse Thomas, Sandrine Dufort, Fabien Rossetti, Matteo Martini, Charles Truillet, Tristan Doussineau, Guillaume Bort, Franck Denat, Frédéric Boschetti, Goran Angelovski, Alexandre Detappe, Yannick Crémillieux, Nathalie Mignet, Bich-Thuy Doan, Benoit Larrat, Sébastien Meriaux, Emmanuel Barbier, Stéphane RouxPeter Fries, Andreas Müller, Marie-Caline Abadjian, Carolyn Anderson, Emmanuelle Canet-Soulas, Penelope Bouziotis, Muriel Barberi-Heyob, Céline Frochot, Camille Verry, Jacques Balosso, Michael Evans, Jacqueline Sidi-Boumedine, Marc Janier, Karl Butterworth, Stephen McMahon, Kevin Prise, Marie-Thérèse Aloy, Dominique Ardail, Claire Rodriguez-Lafrasse, Erika Porcel, Sandrine Lacombe, Ross Berbeco, Awatef Allouch, Jean-Luc Perfettini, Cyrus Chargari, Eric Deutsch, Géraldine Le Duc, Olivier Tillement

*Corresponding author for this work

Research output: Contribution to journalArticle

10 Citations (Scopus)
176 Downloads (Pure)

Abstract

AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes with the second generation of AGuIX nanoparticles and the first preliminary results on human.

Original languageEnglish
Article number20180365
Number of pages19
JournalBritish Journal of Radiology
Volume92
Issue number1093
Early online date18 Sep 2018
DOIs
Publication statusPublished - 01 Jan 2019

Fingerprint

Clinical Medicine
Gadolinium
Nanoparticles
Radiation-Sensitizing Agents
Siloxanes
Toxicity Tests
Brain Neoplasms
Intravenous Administration
Haplorhini
Rodentia
Melanoma
Permeability
Lung Neoplasms
Neck
Radiotherapy
Animal Models
Head
Clinical Trials
Theranostic Nanomedicine
Neoplasms

Cite this

Lux, F., Tran, V. L., Thomas, E., Dufort, S., Rossetti, F., Martini, M., ... Tillement, O. (2019). AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. British Journal of Radiology, 92(1093), [20180365]. https://doi.org/10.1259/bjr.20180365
Lux, François ; Tran, Vu Long ; Thomas, Eloïse ; Dufort, Sandrine ; Rossetti, Fabien ; Martini, Matteo ; Truillet, Charles ; Doussineau, Tristan ; Bort, Guillaume ; Denat, Franck ; Boschetti, Frédéric ; Angelovski, Goran ; Detappe, Alexandre ; Crémillieux, Yannick ; Mignet, Nathalie ; Doan, Bich-Thuy ; Larrat, Benoit ; Meriaux, Sébastien ; Barbier, Emmanuel ; Roux, Stéphane ; Fries, Peter ; Müller, Andreas ; Abadjian, Marie-Caline ; Anderson, Carolyn ; Canet-Soulas, Emmanuelle ; Bouziotis, Penelope ; Barberi-Heyob, Muriel ; Frochot, Céline ; Verry, Camille ; Balosso, Jacques ; Evans, Michael ; Sidi-Boumedine, Jacqueline ; Janier, Marc ; Butterworth, Karl ; McMahon, Stephen ; Prise, Kevin ; Aloy, Marie-Thérèse ; Ardail, Dominique ; Rodriguez-Lafrasse, Claire ; Porcel, Erika ; Lacombe, Sandrine ; Berbeco, Ross ; Allouch, Awatef ; Perfettini, Jean-Luc ; Chargari, Cyrus ; Deutsch, Eric ; Le Duc, Géraldine ; Tillement, Olivier. / AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. In: British Journal of Radiology. 2019 ; Vol. 92, No. 1093.
@article{5041461182664c5791bedc4f87daa74e,
title = "AGuIX{\circledR} from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine",
abstract = "AGuIX{\circledR} are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes with the second generation of AGuIX nanoparticles and the first preliminary results on human.",
author = "Fran{\cc}ois Lux and Tran, {Vu Long} and Elo{\"i}se Thomas and Sandrine Dufort and Fabien Rossetti and Matteo Martini and Charles Truillet and Tristan Doussineau and Guillaume Bort and Franck Denat and Fr{\'e}d{\'e}ric Boschetti and Goran Angelovski and Alexandre Detappe and Yannick Cr{\'e}millieux and Nathalie Mignet and Bich-Thuy Doan and Benoit Larrat and S{\'e}bastien Meriaux and Emmanuel Barbier and St{\'e}phane Roux and Peter Fries and Andreas M{\"u}ller and Marie-Caline Abadjian and Carolyn Anderson and Emmanuelle Canet-Soulas and Penelope Bouziotis and Muriel Barberi-Heyob and C{\'e}line Frochot and Camille Verry and Jacques Balosso and Michael Evans and Jacqueline Sidi-Boumedine and Marc Janier and Karl Butterworth and Stephen McMahon and Kevin Prise and Marie-Th{\'e}r{\`e}se Aloy and Dominique Ardail and Claire Rodriguez-Lafrasse and Erika Porcel and Sandrine Lacombe and Ross Berbeco and Awatef Allouch and Jean-Luc Perfettini and Cyrus Chargari and Eric Deutsch and {Le Duc}, G{\'e}raldine and Olivier Tillement",
year = "2019",
month = "1",
day = "1",
doi = "10.1259/bjr.20180365",
language = "English",
volume = "92",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "1093",

}

Lux, F, Tran, VL, Thomas, E, Dufort, S, Rossetti, F, Martini, M, Truillet, C, Doussineau, T, Bort, G, Denat, F, Boschetti, F, Angelovski, G, Detappe, A, Crémillieux, Y, Mignet, N, Doan, B-T, Larrat, B, Meriaux, S, Barbier, E, Roux, S, Fries, P, Müller, A, Abadjian, M-C, Anderson, C, Canet-Soulas, E, Bouziotis, P, Barberi-Heyob, M, Frochot, C, Verry, C, Balosso, J, Evans, M, Sidi-Boumedine, J, Janier, M, Butterworth, K, McMahon, S, Prise, K, Aloy, M-T, Ardail, D, Rodriguez-Lafrasse, C, Porcel, E, Lacombe, S, Berbeco, R, Allouch, A, Perfettini, J-L, Chargari, C, Deutsch, E, Le Duc, G & Tillement, O 2019, 'AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine', British Journal of Radiology, vol. 92, no. 1093, 20180365. https://doi.org/10.1259/bjr.20180365

AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. / Lux, François; Tran, Vu Long; Thomas, Eloïse; Dufort, Sandrine; Rossetti, Fabien; Martini, Matteo; Truillet, Charles; Doussineau, Tristan; Bort, Guillaume; Denat, Franck; Boschetti, Frédéric; Angelovski, Goran; Detappe, Alexandre; Crémillieux, Yannick; Mignet, Nathalie; Doan, Bich-Thuy; Larrat, Benoit; Meriaux, Sébastien; Barbier, Emmanuel; Roux, Stéphane; Fries, Peter; Müller, Andreas; Abadjian, Marie-Caline; Anderson, Carolyn; Canet-Soulas, Emmanuelle; Bouziotis, Penelope; Barberi-Heyob, Muriel; Frochot, Céline; Verry, Camille; Balosso, Jacques; Evans, Michael; Sidi-Boumedine, Jacqueline; Janier, Marc; Butterworth, Karl; McMahon, Stephen; Prise, Kevin; Aloy, Marie-Thérèse; Ardail, Dominique; Rodriguez-Lafrasse, Claire; Porcel, Erika; Lacombe, Sandrine; Berbeco, Ross; Allouch, Awatef; Perfettini, Jean-Luc; Chargari, Cyrus; Deutsch, Eric; Le Duc, Géraldine; Tillement, Olivier.

In: British Journal of Radiology, Vol. 92, No. 1093, 20180365, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

AU - Lux, François

AU - Tran, Vu Long

AU - Thomas, Eloïse

AU - Dufort, Sandrine

AU - Rossetti, Fabien

AU - Martini, Matteo

AU - Truillet, Charles

AU - Doussineau, Tristan

AU - Bort, Guillaume

AU - Denat, Franck

AU - Boschetti, Frédéric

AU - Angelovski, Goran

AU - Detappe, Alexandre

AU - Crémillieux, Yannick

AU - Mignet, Nathalie

AU - Doan, Bich-Thuy

AU - Larrat, Benoit

AU - Meriaux, Sébastien

AU - Barbier, Emmanuel

AU - Roux, Stéphane

AU - Fries, Peter

AU - Müller, Andreas

AU - Abadjian, Marie-Caline

AU - Anderson, Carolyn

AU - Canet-Soulas, Emmanuelle

AU - Bouziotis, Penelope

AU - Barberi-Heyob, Muriel

AU - Frochot, Céline

AU - Verry, Camille

AU - Balosso, Jacques

AU - Evans, Michael

AU - Sidi-Boumedine, Jacqueline

AU - Janier, Marc

AU - Butterworth, Karl

AU - McMahon, Stephen

AU - Prise, Kevin

AU - Aloy, Marie-Thérèse

AU - Ardail, Dominique

AU - Rodriguez-Lafrasse, Claire

AU - Porcel, Erika

AU - Lacombe, Sandrine

AU - Berbeco, Ross

AU - Allouch, Awatef

AU - Perfettini, Jean-Luc

AU - Chargari, Cyrus

AU - Deutsch, Eric

AU - Le Duc, Géraldine

AU - Tillement, Olivier

PY - 2019/1/1

Y1 - 2019/1/1

N2 - AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes with the second generation of AGuIX nanoparticles and the first preliminary results on human.

AB - AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes with the second generation of AGuIX nanoparticles and the first preliminary results on human.

UR - http://www.scopus.com/inward/record.url?scp=85057388723&partnerID=8YFLogxK

U2 - 10.1259/bjr.20180365

DO - 10.1259/bjr.20180365

M3 - Article

C2 - 30226413

VL - 92

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1093

M1 - 20180365

ER -